{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:02:34Z","timestamp":1753876954545,"version":"3.41.2"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Jiangsu Hengrui Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>What is the minimum effective dose of SHR7280, a novel oral GnRH antagonist, to prevent a premature LH surge in women undergoing controlled ovarian hyperstimulation for ART?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>SHR7280 at 200\u2009mg once every 12\u2009h (Q12h) was the minimal effective dose to suppress an LH surge and was associated with high-quality embryos, and a high clinical pregnancy rate. SHR7280 was well-tolerated and safe.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Currently, all approved GnRH antagonists for preventing a premature LH surge are injectable, peptide-based formulations, which can cause inconvenience and injection site reactions. There is a significant unmet need for an orally available GnRH antagonist to address this issue. SHR7280 has previously demonstrated effective suppression of LH levels in healthy volunteers in phase 1 trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>This multi-center, open-label, dosing-finding phase 2 trial was conducted between 26 January 2022 and 3 August 2023 in 85 infertile women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>The starting dose of SHR7280 was 300\u2009mg Q12h, followed by dose exploration in two lower dose groups (200\u2009mg Q12h and 200\u2009mg Q24h) sequentially. Dose exploration was terminated if an LH surge occurred. SHR7280 was administrated orally starting on Day 5 of recombinant human FSH stimulation until hCG administration. The primary endpoint was the rate of premature LH surge inhibition during SHR7280 treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Eighty-five patients received SHR7280: 300\u2009mg Q12h, n\u2009=\u200940; 200\u2009mg Q12h, n\u2009=\u200942; 200\u2009mg Q24h, n\u2009=\u20093. The mean (\u2009\u00b1\u2009SD) duration of SHR7280 treatment was 5.7\u2009\u00b1\u20091.2, 5.7\u2009\u00b1\u20091.3, and 3.7\u2009\u00b1\u20090.6\u2009days, respectively. The rate of LH surge inhibition was 99% (95% CI 94\u2013100) in all patients, 100% (95% CI 91\u2013100) in the 300\u2009mg Q12h group, 100% (95% CI 92\u2013100) in the 200\u2009mg Q12h group, and 67% (95% CI 9\u201399) in the 200\u2009mg Q24h group. Two hundred milligrams Q12h was established as the minimal effective dose. Embryological and pregnancy outcomes were comparable in the 300 and 200\u2009mg Q12h groups. In the 200\u2009mg Q12h group, the mean (\u2009\u00b1\u2009SD) number of oocytes retrieved per patient, two-pronucleate zygotes, and high-quality embryos was 10.7\u2009\u00b1\u20094.6, 6.9\u2009\u00b1\u20093.2, and 3.9\u2009\u00b1\u20092.6, respectively; among patients receiving fresh embryo transfer, 62% (95% CI 44\u201378) were tested positive for serum \u03b2-hCG and 53% (95% CI 35\u201370) were confirmed to be clinically pregnant per transfer. No spontaneous ovulation occurred on the day of oocyte retrieval. In all 85 patients, treatment-related adverse events were reported in 1 (1%; mild in severity) patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The sample size was moderate and there was no standard peptide-based GnRH antagonist as a control group. Additionally, the performance of SHR7280 in specific populations, such as patients with diminished ovarian reserve and at high risk of OHSS, remains to be established. Further research is also needed to determine the recommended dose in patients with high BMI, intending for frozen embryo transfer, and using a GnRH agonist as trigger. Moreover, the study included only Chinese patients and allowed up to 2 embryos per transfer. The efficacy and safety of SHR7280 in other racial groups and regions require further investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Findings from this phase 2 trial suggest that an oral GnRH antagonist could be an effective alternative for preventing a premature LH surge in ART.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>This study was funded by Jiangsu Hengrui Pharmaceuticals. Z.L., Yu.S., C.S., Hong.C., and K.S. were employees of Jiangsu Hengrui Pharmaceuticals at the time of study. All other authors have no conflicts of interests to declare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>NCT05082233.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deaf082","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T18:31:56Z","timestamp":1747333916000},"page":"1357-1365","source":"Crossref","is-referenced-by-count":0,"title":["SHR7280, an oral gonadotropin-releasing hormone antagonist, for the prevention of premature luteinizing hormone surge in controlled ovarian hyperstimulation: a dose-finding, phase 2 trial"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6074-0663","authenticated-orcid":false,"given":"Hongbin","family":"Chi","sequence":"first","affiliation":[{"name":"State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology\/National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital , Beijing,","place":["China"]},{"name":"Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University , Beijing,","place":["China"]},{"name":"Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology , Beijing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology\/National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital , Beijing,","place":["China"]},{"name":"Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University , Beijing,","place":["China"]},{"name":"Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology , Beijing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology , Wuhan,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueru","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Reproductive Aid Gynecology, Tianjin Medical University General Hospital , Tianjin,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Air Force Military University Tangdu Hospital , Xi\u2019an,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianhong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, West China Second University Hospital, Sichuan University , Chengdu,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-0874","authenticated-orcid":false,"given":"Yunxia","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University , Hefei,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine Research Center, The Sixth Affiliated Hospital, Sun Yat-Sen University , Guangzhou,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jichun","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine Center, Shengjing Hospital of China Medical University , Shenyang,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-105X","authenticated-orcid":false,"given":"Yichun","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, The Third Affiliated Hospital of Zhengzhou University , Zhengzhou,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0118-3382","authenticated-orcid":false,"given":"Feiyang","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Jiangsu Province People\u2019s Hospital\/The First Affiliated Hospital with Nanjing Medical University , Nanjing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Xiangya Hospital of Central South University , Changsha,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeli","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-1376","authenticated-orcid":false,"given":"Jie","family":"Qiao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology\/National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital , Beijing,","place":["China"]},{"name":"Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University , Beijing,","place":["China"]},{"name":"Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology , Beijing,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2025070301515235600_deaf082-B1","first-page":"CD001750","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025070301515235600_deaf082-B2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/15.3.526","article-title":"Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group","volume":"15","author":"Albano","year":"2000","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0015-0282(97)81407-0","article-title":"Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation","volume":"67","author":"Albano","year":"1997","journal-title":"Fertil Steril"},{"key":"2025070301515235600_deaf082-B4","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/humrep\/15.7.1490","article-title":"Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group","volume":"15","author":"Borm","year":"2000","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.rbmo.2020.11.013","article-title":"The freeze-all strategy after IVF: which indications?","volume":"42","author":"Bourdon","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2025070301515235600_deaf082-B6","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/humrep\/deab198","article-title":"International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014","volume":"36","author":"Chambers","year":"2021","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/humrep\/16.4.644","article-title":"Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation","volume":"16","author":"European and Middle East Orgalutran Study Group","year":"2001","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/humupd\/dmac012","article-title":"The LH surge and ovulation re-visited: a systematic review and meta-analysis and implications for true natural cycle frozen thawed embryo transfer","volume":"28","author":"Erden","year":"2022","journal-title":"Hum Reprod Update"},{"key":"2025070301515235600_deaf082-B9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0015-0282(16)49159-4","article-title":"Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression","volume":"45","author":"Fleming","year":"1986","journal-title":"Fertil Steril"},{"key":"2025070301515235600_deaf082-B10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0015-0282(00)01638-1","article-title":"Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation","volume":"75","author":"Fluker","year":"2001","journal-title":"Fertil Steril"},{"key":"2025070301515235600_deaf082-B11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet Gynecol Surv"},{"key":"2025070301515235600_deaf082-B12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2010.03.028","article-title":"Preventing ovarian hyperstimulation syndrome: guidance for the clinician","volume":"94","author":"Humaidan","year":"2010","journal-title":"Fertil Steril"},{"key":"2025070301515235600_deaf082-B13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s40265-022-01753-9","article-title":"Linzagolix: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"2025070301515235600_deaf082-B14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40265-018-0977-4","article-title":"Elagolix: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"2025070301515235600_deaf082-B15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum Reprod Update"},{"key":"2025070301515235600_deaf082-B16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/humrep\/dei386","article-title":"Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial","volume":"21","author":"Lambalk","year":"2006","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12916-023-02834-6","article-title":"Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"key":"2025070301515235600_deaf082-B18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/oxfordjournals.humrep.a137105","article-title":"The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer","volume":"5","author":"Loumaye","year":"1990","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0015-0282(16)57495-0","article-title":"Selective use of leuprolide acetate in women undergoing superovulation with intrauterine insemination results in significant improvement in pregnancy outcome","volume":"63","author":"Manzi","year":"1995","journal-title":"Fertil Steril"},{"key":"2025070301515235600_deaf082-B20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-019-01105-0","article-title":"Relugolix: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"2025070301515235600_deaf082-B21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/humupd\/dmz037","article-title":"Ovarian stimulation for freeze-all IVF cycles: a systematic review","volume":"26","author":"Mizrachi","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2025070301515235600_deaf082-B22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1472-6483(10)62163-3","article-title":"Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences","volume":"6","author":"Olivennes","year":"2003","journal-title":"Reprod Biomed Online"},{"key":"2025070301515235600_deaf082-B23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3109\/09513590.2012.665103","article-title":"A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates","volume":"28","author":"Qiao","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"2025070301515235600_deaf082-B24","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/humrep\/dead197","article-title":"ART in Europe, 2019: results generated from European registries by ESHRE\u2020","volume":"38","author":"Smeenk","year":"2023","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B25","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.18632\/aging.102497","article-title":"Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017: results from a global burden of disease study, 2017","volume":"11","author":"Sun","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"2025070301515235600_deaf082-B26","first-page":"940","article-title":"Chinese expert consensus on numbers of embryos transferred","volume":"27","author":"Sun","year":"2018","journal-title":"J Reprod Med"},{"key":"2025070301515235600_deaf082-B27","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/humrep\/13.11.3023","article-title":"A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)","volume":"13","author":"The Ganirelix Dose-Finding Study Group","year":"1998","journal-title":"Hum Reprod"},{"key":"2025070301515235600_deaf082-B28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.fertnstert.2005.03.016","article-title":"Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies","volume":"84","author":"Wilcox","year":"2005","journal-title":"Fertil Steril"},{"key":"2025070301515235600_deaf082-B29","doi-asserted-by":"crossref","first-page":"1027648","DOI":"10.3389\/fphar.2022.1027648","article-title":"Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women","volume":"13","author":"Xu","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/7\/1357\/63198565\/deaf082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/40\/7\/1357\/63198565\/deaf082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:52:09Z","timestamp":1751521929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/40\/7\/1357\/8133168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaf082","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"type":"print","value":"0268-1161"},{"type":"electronic","value":"1460-2350"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,15]]}}}